Prognostic Value of p16 Promoter Hypermethylation in Colorectal Cancer: A Meta-Analysis

Whether or not p16 promoter hypermethylation has any prognostic value on the survival of patients with colorectal cancer (CRC) is uncertain. A meta-analysis was therefore conducted on the overall survival involving 16 studies with 3968 patients and disease-free survival involving six studies with 10...

Full description

Saved in:
Bibliographic Details
Published inCancer investigation Vol. 32; no. 2; pp. 43 - 52
Main Authors Jiang, Wenjie, Wang, Pei-Ge, Zhan, Yuzhu, Zhang, Dongfeng
Format Journal Article
LanguageEnglish
Published England Informa Healthcare 01.02.2014
Taylor & Francis
Subjects
Colorectal cancer
Colorectal Neoplasms - genetics
Cyclin-Dependent Kinase Inhibitor p16
DNA Methylation
Gene Expression Regulation, Neoplastic
Genes, p16
Humans
Meta-analysis
Methylation
Neoplasm Proteins - genetics
P16 gene
Prognosis
Promoter Regions, Genetic
Prospective Studies
Survival Analysis
Online AccessGet full text

Cover

More Information
Summary:Whether or not p16 promoter hypermethylation has any prognostic value on the survival of patients with colorectal cancer (CRC) is uncertain. A meta-analysis was therefore conducted on the overall survival involving 16 studies with 3968 patients and disease-free survival involving six studies with 1091 cases, respectively. The promoter hypermethylation was found to be significantly associated with shorter survival compared to controls, which was not only stable according to influence analysis and cumulative meta-analysis but also conclusive according to trial sequential meta-analysis. The meta-analysis supports the hypermethylation as an independent adverse prognostic factor for CRC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0735-7907
1532-4192
DOI:10.3109/07357907.2013.861476